PT  - JOURNAL ARTICLE
AU  - McPherson, Susan
AU  - Freedman, David E.P.
TI  - Psychological outcomes of 12-15 year olds with gender dysphoria receiving pubertal suppression: assessing reliable change and recovery
AID  - 10.1101/2023.05.30.23290763
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.05.30.23290763
4099  - http://medrxiv.org/content/early/2023/06/01/2023.05.30.23290763.short
4100  - http://medrxiv.org/content/early/2023/06/01/2023.05.30.23290763.full
AB  - In 2021 the results of the first UK study of GnHRA treatment in young adolescents was published. Based on means testing alone, the study found no deterioration in psychological wellbeing. The aim of the current study is to re-analyse the data to assess Reliable Change and Recovery rates in order to assess individual level change and provide a more accurate assessment of treatment risks. The data from the original uncontrolled prospective observational study were collected within a national specialist service for children with gender dysphoria. Participants were 44 12-15 year olds diagnosed with gender dysphoria meeting pre-specified eligibility criteria for GnHRA treatment. Puberty was suppressed using “triptorelin”; participants were followed-up for 36 months. A range of outcomes was assessed including response to pubertal suppression; bone health; adverse events; and psychological outcomes. Because the primary justification for use of GnHRA treatment in this age group is to relieve psychological distress caused by onset of puberty, our analysis focuses on general psychopathology measured by the Child Behaviour Checklist and Youth Self Report form. Contrary to conclusions of the original study, our results indicate that between 15% and 34% of participants reliably deteriorated depending on the subscale and time point. Relatively few participants fell into the borderline or clinical range at baseline (37%-58% depending on the scale and time point); recovery rates were low and fell to zero on both self-report and parent-report at 36 months. Rates of reliable deterioration as well as recovery rates were comparatively worse than typical child and adolescent mental health services where recovery rates of around 50% are found. These findings are concerning and indicate an urgent need to re-evaluate conclusions drawn from the original study and for more detailed analysis of outcomes to inform ongoing use of GnHRA treatment in young adolescents in the UK.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAClinical ProtocolsNAFunding StatementThe authors received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The article is a secondary data analysis. Original study data were anonymised and lodged at the UK Data Archive in a format suitable for use with no further ethical approval or consent required, as agreed with the Health Research Authority. Please see the original publication (cited in the paper) for more detailed information on the ethics approval which was obtained from the National Research Ethics Service (NRES: reference 10/H0713/79) in February 2011. Subsequently, the team had discussions with the Health Research Authority who provided permission for data to be deposited with the UK Data Archive on the condition that sensitive data was removed to minimise disclosure risk of personal information.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableThe data underlying the results presented in this study are available from the UK Data Service (DOI: 10.5255/UKDA-SN-854413). 10.5255/UKDA-SN-854413